Thiazolidinediones and Fractures in Men and Women

被引:97
作者
Dormuth, Colin R. [1 ,4 ]
Carney, Greg [4 ]
Carleton, Bruce [5 ,6 ]
Bassett, Ken [1 ,2 ,4 ]
Wright, Jarnes M. [1 ,3 ,4 ]
机构
[1] Univ British Columbia, Dept Anesthesiol Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada
[2] Univ British Columbia, Dept Family Practice, Vancouver, BC V5Z 1M9, Canada
[3] Univ British Columbia, Dept Med, Vancouver, BC, Canada
[4] Univ British Columbia, Therapeut Initiat, Vancouver, BC V5Z 1M9, Canada
[5] Univ British Columbia, Fac Med Pediat & Pharmaceut Sci, Pharmaceut Outcomes & Policy Innovat Programme, Vancouver, BC V5Z 1M9, Canada
[6] Child & Family Res Inst, Pharmaceut Outcomes Programme, Vancouver, BC, Canada
关键词
BONE-MINERAL DENSITY; TYPE-2; DIABETES-MELLITUS; CONTROLLED-TRIAL; POSTMENOPAUSAL WOMEN; HIP-FRACTURES; HEART-FAILURE; COST-ANALYSIS; RISK; ROSIGLITAZONE; DISCHARGE;
D O I
10.1001/archinternmed.2009.214
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Clinical trials and meta-analyses have found that rosiglitazone maleate, a thiazolidinedione that is prescribed for type 2 diabetes mellitus, increases the risk of fractures in women. The association between the use of thiazolidinediones and fractures in men and women is not adequately understood. Methods: We conducted a prospective cohort study. The primary outcome was peripheral fractures in men and women who were exposed to thiazolidinediones compared with sulfonylureas. We studied 84 339 patients from British Columbia, Canada, who began treatment with a thiazolidinedione or a sulfonylurea. The association between the use of thiazolidinediones and fractures was examined using multivariate-adjusted Cox models. Results: The mean age of the patients in the study was 59 years, and 43% were women. In this cohort, treatment with a thiazolidinedione was associated with a 28% increased risk of peripheral fractures compared with treatment with a sulfonylurea (hazard ratio [HR], 1.28; 95% confidence interval [CI], 1.10-1.48). The use of pioglitazone hydrochloride was associated with an increased risk of peripheral fracture of 77% in women (HR, 1.76; 95% CI 1.32-2.38). Compared with exposure to sulfonylureas, exposure to pioglitazone was associated with more peripheral fractures in men (HR, 1.6 1; 95% CI 1.18-2.20), but we did not observe a similar association with exposure to rosiglitazone (HR, 1.00; 95% CI, 0.75-1.34). Conclusions: Both men and women who take thiazolidinediones could be at increased risk of fractures. Pioglitazone may be more strongly associated with fractures than rosiglitazone. Larger observational studies are needed, and fracture data from clinical trials need to be fully published so that fracture risks can be known with greater certainty.
引用
收藏
页码:1395 / 1402
页数:8
相关论文
共 37 条
[1]   Calculating the number needed to treat for trials where the outcome is time to an event [J].
Altman, DG ;
Andersen, PK .
BRITISH MEDICAL JOURNAL, 1999, 319 (7223) :1492-1495
[2]  
[Anonymous], J CLIN EPIDEMIOL
[3]  
[Anonymous], 2005, NAT DIAB FACT SHEET
[4]   Rosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic women [J].
Berberoglu, Zehra ;
Gursoy, Alptekin ;
Bayraktar, Nilufer ;
Yazici, Ayse Canan ;
Tutuncu, Neslihan Bascil ;
Demirag, Nilgun Guvener .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (09) :3523-3530
[5]   Risk of fracture in women with type 2 diabetes: The Women's Health Initiative Observational Study [J].
Bonds, Denise E. ;
Larson, Joseph C. ;
Schwartz, Ann V. ;
Strotmeyer, Elsa S. ;
Robbins, John ;
Rodriguez, Beatriz L. ;
Johnson, Karen C. ;
Margolis, Karen L. .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (09) :3404-3410
[6]   Bone mineral density and fracture risk in type-2 diabetes mellitus: the Rotterdam Study. [J].
de Liefde, II ;
van der Klift, M ;
de Laet, CEDH ;
van Daele, PLA ;
Hofman, A ;
Pols, HAP .
OSTEOPOROSIS INTERNATIONAL, 2005, 16 (12) :1713-1720
[7]   Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: Some issues with meta-analyses [J].
Delmas, PD ;
Li, ZQ ;
Cooper, C .
JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 (02) :330-337
[8]  
DILLON JA, INCREASED INCIDENCE
[9]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[10]   THE ACCURACY OF MEDICARES HOSPITAL CLAIMS DATA - PROGRESS HAS BEEN MADE, BUT PROBLEMS REMAIN [J].
FISHER, ES ;
WHALEY, FS ;
KRUSHAT, WM ;
MALENKA, DJ ;
FLEMING, C ;
BARON, JA ;
HSIA, DC .
AMERICAN JOURNAL OF PUBLIC HEALTH, 1992, 82 (02) :243-248